Professor Gisli Jenkins completed his medical training at University of Southampton before undertaking postgraduate training in respiratory medicine in London.
During this time, he undertook basic scientific training funded by an ARC fellowship and obtained a PhD in Biochemistry from University College London before doing post-doctoral studies at University of California at San Francisco funded by an ARC Clinician Scientist Fellowship.
In 2021, Professor Jenkins moved to Imperial College, London to lead the Margaret Turner Warwick Centre for Fibrosing Lung Disease at the National Heart and Lung Institute.
Currently, he is the Familial Pulmonary Fibrosis lead for the Genomics England Clinical Interpretation Partnership in Respiratory Medicine and is Post Hospitalisation (PHOSP)-COVID study Fibrosis Working Group lead, also leading the UK interstitial Lung Disease consortium.
Professor Jenkins’ clinical and research focus is on interstitial lung disease and idiopathic fibrosis.
The three major themes of his research are:
Professor Gisli Jenkins has been the joint editor-in-chief of the official journal of the British Thoracic Society since 2015 and was chair of the British Thoracic Society Science and Research Committee from 2016-2018.
In addition, he is also the President of Action for Pulmonary Fibrosis and is the Principle Investigator of the Global REMAP-ILD study.
Professor Jenkins has sat on several American Thoracic Society Committees and is co-chair of the International Colloquium of Lung and Airway Fibrosis.
Additionally, he is a founding Trustee of the patient charity Action for Pulmonary Fibrosis and is the clinical lead for the James Lind Alliance Priority Setting Partnership.
In 2020, Professor Gisli Jenkins was awarded the European Society Gold Medal in Idiopathic Pulmonary Fibrosis.